ReSPECT-GBM Study Now Featured by the American Brain Tumor Association

by | Nov 14, 2025 | GBM

Plus Therapeutics is proud to share that the ReSPECT-GBM clinical trial is now a featured study on the American Brain Tumor Association (ABTA) website. This recognition highlights the growing visibility and clinical importance of our work to develop new therapeutic options for patients with recurrent malignant glioma and glioblastoma (GBM).

View the ABTA listing here:
https://lnkd.in/gdhyZ3BX

Addressing the Need for New Options in Recurrent Glioblastoma

Glioblastoma remains one of the most aggressive and difficult-to-treat brain cancers. Even after standard treatment approaches—including surgery, radiation, and chemotherapy—many patients experience tumor recurrence. When recurrence occurs, treatment options are limited, and there is a critical need for new therapeutic strategies that can target tumor cells more effectively and safely within the central nervous system.

The ReSPECT-GBM Phase 2 clinical trial is evaluating an investigational radiotherapeutic designed to deliver targeted radiation directly to the site of the tumor, with the goal of improving outcomes for patients facing recurrent disease.

About the ReSPECT-GBM Clinical Trial

The ReSPECT-GBM study is actively recruiting adults with malignant glioma, including glioblastoma, whose cancer has progressed following standard-of-care therapy. The trial is designed for patients who have:

  • Undergone previous surgery, radiation, or chemotherapy

  • Experienced tumor recurrence or continued growth

  • Are seeking alternative or additional investigational treatment options

This study represents an important step forward in exploring precision radiotherapeutics for complex CNS tumors.

To learn more about eligibility criteria, study design, and participating clinical sites, visit:
https://lnkd.in/dP9Gun6C

Our Commitment to Advancing CNS Cancer Research

At Plus Therapeutics, our mission is to develop next-generation radiotherapeutics that address some of the most significant unmet needs in neuro-oncology. The inclusion of ReSPECT-GBM as a featured ABTA clinical trial underscores the importance of ongoing research aimed at improving outcomes for patients with recurrent GBM.

We encourage individuals, caregivers, and clinicians seeking new options to explore the trial details and consider whether the ReSPECT-GBM study may be an appropriate next step.